Kezar Life Sciences (NASDAQ:KZR) Stock Price Up 10.4%

Shares of Kezar Life Sciences Inc (NASDAQ:KZR) rose 10.4% during trading on Friday . The stock traded as high as $3.25 and last traded at $2.87, approximately 269,000 shares changed hands during trading. An increase of 185% from the average daily volume of 94,544 shares. The stock had previously closed at $2.60.

KZR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Kezar Life Sciences in a research report on Monday, October 21st. ValuEngine raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 6th. Finally, Zacks Investment Research raised shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Tuesday, November 12th. Five research analysts have rated the stock with a buy rating, Kezar Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $9.13.

The business has a fifty day moving average of $3.12 and a 200-day moving average of $6.81. The company has a debt-to-equity ratio of 0.07, a quick ratio of 16.67 and a current ratio of 16.67. The company has a market capitalization of $47.85 million, a P/E ratio of -1.27 and a beta of 0.88.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. Sell-side analysts anticipate that Kezar Life Sciences Inc will post -1.89 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. lifted its holdings in shares of Kezar Life Sciences by 105.7% in the 2nd quarter. Victory Capital Management Inc. now owns 461,453 shares of the company’s stock worth $3,558,000 after purchasing an additional 237,110 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Kezar Life Sciences by 33.7% in the 2nd quarter. Marshall Wace LLP now owns 53,016 shares of the company’s stock worth $409,000 after purchasing an additional 13,353 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Kezar Life Sciences by 923.4% in the 2nd quarter. Morgan Stanley now owns 74,982 shares of the company’s stock worth $578,000 after purchasing an additional 67,655 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Kezar Life Sciences in the 2nd quarter worth $112,000. Finally, BlackRock Inc. lifted its holdings in shares of Kezar Life Sciences by 32.9% in the 2nd quarter. BlackRock Inc. now owns 844,391 shares of the company’s stock worth $6,512,000 after purchasing an additional 208,816 shares in the last quarter. Institutional investors own 54.10% of the company’s stock.

Kezar Life Sciences Company Profile (NASDAQ:KZR)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Further Reading: What is the Fibonacci sequence?

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.